What do systematic reviews say?

Oral ferric maltol vs IV ferric carboxymaltose

It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 2.95 [0.98, 8.91]
  1 study · 252 participants
  Very low

Dextrose gel vs placebo

Dextrose gel showed no clear difference in separation from mother for treatment of hypoglycaemia (infant nursed… compared with placebo (low certainty).

• Oral dextrose gel to prevent hypoglycaemia in at‐risk neonates 2023 · Cochrane Headline outcomes only
  RR 1.12 [0.81, 1.55]
  2 studies · 2548 participants
  Low

IV ferric carboxymaltose vs oral iron

IV ferric carboxymaltose showed no clear difference in number of responders ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 1.17 [0.95, 1.43]
  1 study · 200 participants
  Low

IV ferric carboxymaltose vs oral iron

It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 8.81 [0.52, 149.07]
  1 study · 200 participants
  Very low

Intervention not reported

The intervention probably leads to lower low Hb deferral ‐ at first donation visit after commencement of… (moderate certainty).

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  RR 0.34 [0.21, 0.55]
  4 studies · 1194 participants
  Moderate

Intervention not reported

The intervention probably leads to lower low Hb deferral ‐ after multiple donation visits (moderate certainty).

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  RR 0.25 [0.15, 0.41]
  3 studies · 793 participants
  Moderate

Intervention not reported

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 847 participants
  Moderate

Intervention not reported

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 406 participants
  Moderate

Intervention not reported

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 640 participants
  Moderate

Intervention not reported

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 619 participants
  Moderate

Intervention not reported

The intervention probably leads to higher adverse effects (any) (moderate certainty).

• Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 2014 · Cochrane Headline outcomes only
  RR 1.6 [1.23, 2.07]
  4 studies · 1748 participants
  Moderate

IM erythropoietin vs oral placebo

It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 3.5 [1.44, 8.48]
  1 study · 34 participants
  Very low

IM erythropoietin vs oral placebo

The review found no eligible studies for this question.

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intravenous preparations vs oral preparations

Intravenous preparations may leads to higher number of responders compared with oral preparations (low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 1.17 [1.05, 1.31]
  5 studies · 927 participants
  Low

Intravenous preparations vs oral preparations

Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  RR 0.39 [0.2, 0.74]
  5 studies · 927 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  33 studies · 3389 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  27 studies · 3089 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 152 participants
  Very low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 522 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1052 participants
  Low